Liquidity ratios measure the company ability to meet its short-term obligations.
Paying user area
Try for free
AbbVie Inc. pages available for free this week:
- Balance Sheet: Assets
- Common-Size Balance Sheet: Assets
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Solvency Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value to EBITDA (EV/EBITDA)
- Present Value of Free Cash Flow to Equity (FCFE)
- Selected Financial Data since 2012
- Total Asset Turnover since 2012
- Price to Book Value (P/BV) since 2012
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to AbbVie Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Liquidity Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The liquidity position, as indicated by the current, quick, and cash ratios, exhibits fluctuating trends over the observed period. Generally, a declining trend in all three ratios is apparent from the beginning of 2023 through the end of 2025, although with some quarterly variations.
- Current Ratio
- The current ratio began at 0.82 in March 2022 and generally increased to 0.96 by December 2022. It then experienced volatility, decreasing to 0.87 by December 2023, and continued a downward trend, reaching 0.67 by December 2025. The lowest point within the period was 0.65 in September 2024. This suggests a decreasing ability to cover short-term liabilities with short-term assets.
- Quick Ratio
- The quick ratio demonstrated an increasing trend from 0.56 in March 2022 to 0.69 in September 2022, remaining stable through December 2022. A subsequent decline began in March 2023, with the ratio falling to 0.41 by December 2025. The quick ratio consistently remained below the current ratio throughout the period, indicating a reliance on inventory to meet current obligations. The most significant decrease occurred between June 2024 and December 2025.
- Cash Ratio
- The cash ratio showed an initial increase from 0.23 in March 2022 to 0.36 in September 2022, followed by a decrease to 0.31 by December 2022. The ratio continued to fluctuate, reaching a peak of 0.44 in March 2024 before declining to 0.12 by December 2025. This represents the most substantial decrease among the three ratios, indicating a diminishing capacity to cover immediate liabilities with only cash and cash equivalents.
The consistent decline in all three ratios towards the end of the period suggests a potential weakening in the short-term liquidity position. While the ratios remained positive throughout the observed timeframe, the downward trajectory warrants further investigation into the underlying causes, such as changes in working capital management, debt levels, or asset utilization.
Current Ratio
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Current assets | |||||||||||||||||||||
| Current liabilities | |||||||||||||||||||||
| Liquidity Ratio | |||||||||||||||||||||
| Current ratio1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Current Ratio, Competitors2 | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Current ratio = Current assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The current ratio exhibited fluctuations over the observed period, spanning from March 31, 2022, to December 31, 2025. Initially, the ratio demonstrated an improving trend, followed by periods of decline and stabilization.
- Initial Trend (Mar 31, 2022 – Dec 31, 2022)
- The current ratio began at 0.82 and generally increased through the end of 2022, reaching 0.96. This suggests an improvement in the company’s ability to cover its short-term liabilities with its short-term assets during this timeframe.
- Subsequent Fluctuations (Mar 31, 2023 – Dec 31, 2024)
- Following the peak in December 2022, the current ratio experienced volatility. It decreased to 0.87 by the end of 2023, then rose to 0.94 in March 2024 before declining again to 0.65 by September 2024. This period indicates inconsistent short-term liquidity performance.
- Recent Performance (Jan 1, 2025 – Dec 31, 2025)
- The ratio remained below 0.75 throughout 2025, ending the period at 0.67. This represents a continued weakening in the company’s short-term liquidity position compared to earlier periods in the analysis. The lowest point was 0.65 in September 2024.
Overall, the current ratio demonstrates a general downward trend when comparing the beginning and end of the analyzed period. While there were periods of improvement, the ratio consistently fell below 1.0 for much of the timeframe, indicating that current liabilities exceeded current assets. The most recent quarters show a concerning trend of sustained lower liquidity.
Quick Ratio
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Cash and equivalents | |||||||||||||||||||||
| Short-term investments | |||||||||||||||||||||
| Accounts receivable, net | |||||||||||||||||||||
| Total quick assets | |||||||||||||||||||||
| Current liabilities | |||||||||||||||||||||
| Liquidity Ratio | |||||||||||||||||||||
| Quick ratio1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Quick Ratio, Competitors2 | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The quick ratio exhibited fluctuations over the observed period, spanning from March 31, 2022, to December 31, 2025. Initially, the ratio demonstrated an improving trend, followed by periods of decline and stabilization. A general observation suggests a decreasing trend in the latter half of the analyzed timeframe.
- Initial Trend (Mar 31, 2022 – Sep 30, 2022)
- The quick ratio began at 0.56 and increased to 0.69 by September 30, 2022. This indicates an improving ability to meet short-term obligations with highly liquid assets during this period. The increase suggests a strengthening of the short-term financial position.
- Stabilization and Decline (Sep 30, 2022 – Dec 31, 2022)
- Following the peak in September 2022, the quick ratio experienced a slight decrease to 0.63 by December 31, 2022, remaining relatively stable. This suggests a leveling off of the short-term liquidity position.
- Fluctuations and Subsequent Decline (Mar 31, 2023 – Dec 31, 2024)
- The ratio fluctuated between 0.66 and 0.59 over the next four quarters, demonstrating some volatility. A more pronounced decline was observed from March 31, 2024, to December 31, 2024, falling from 0.72 to 0.43. This indicates a weakening ability to cover immediate liabilities with quick assets.
- Recent Performance (Mar 31, 2025 – Dec 31, 2025)
- The quick ratio remained subdued in the final year of the period, oscillating between 0.48 and 0.41. The final reported value of 0.41 represents the lowest point in the observed timeframe, signaling a continued challenge in meeting short-term obligations without relying on inventory liquidation.
The observed trend in the quick ratio suggests a potential deterioration in short-term liquidity. While initial periods showed improvement, the latter portion of the analyzed period indicates a weakening ability to cover current liabilities with readily available assets. Further investigation into the components of quick assets and current liabilities would be necessary to determine the underlying causes of these fluctuations.
Cash Ratio
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Cash and equivalents | |||||||||||||||||||||
| Short-term investments | |||||||||||||||||||||
| Total cash assets | |||||||||||||||||||||
| Current liabilities | |||||||||||||||||||||
| Liquidity Ratio | |||||||||||||||||||||
| Cash ratio1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Cash Ratio, Competitors2 | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The cash ratio for the analyzed period demonstrates fluctuations, generally indicating a variable capacity to meet short-term obligations with highly liquid assets. An initial upward trend is observed, followed by periods of decline and subsequent recovery.
- Overall Trend
- The cash ratio began at 0.23 in March 2022 and generally increased through September 2022, peaking at 0.36. A subsequent decline occurred through March 2023, reaching 0.24. The ratio experienced another increase, reaching 0.38 in September 2023, before decreasing again to 0.31 by December 2023. A significant drop is then observed through December 2024, falling to 0.14, followed by a slight recovery to 0.12 by December 2025.
- Peak and Trough Values
- The highest cash ratio recorded during the period was 0.38 in September 2023. The lowest value was 0.12 in December 2025. This represents a substantial range, suggesting considerable shifts in the company’s short-term liquidity position.
- Recent Performance (2024-2025)
- From March 2024 through December 2025, the cash ratio exhibited a consistent downward trend, decreasing from 0.44 to 0.12. This indicates a weakening ability to cover current liabilities with available cash. The decline appears particularly pronounced in the latter half of 2024 and continues into 2025.
- Relationship between Cash Assets and Current Liabilities
- While total cash assets increased significantly from March 2022 to September 2022, and again from March 2024 to March 2025, current liabilities experienced more substantial and consistent increases over the entire period. This disparity contributed to the overall fluctuations and eventual decline in the cash ratio. The increase in current liabilities appears to outpace the growth in cash assets, particularly in the later periods.
The observed trends suggest a potential need for monitoring the composition of current liabilities and the management of cash resources. The recent decline in the cash ratio warrants further investigation to understand the underlying drivers and potential implications for short-term financial stability.